Cicaprost (Synonyms: ZK 96480) |
| Catalog No.GC41222 |
시카프로스트(ZK 96480)는 프로스타사이클린 수용체(IP) 작용제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 94079-80-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Prostaglandin I2 (PGI2, prostacyclin) is the most potent endogenous vasodilator that affects both the systemic and pulmonary circulation.[1] Cicaprost is a PGI2 analog that is orally active with prolonged availability in vivo, having a terminal half life in plasma of one hour.[2][3] In addition to their effects on smooth muscle, PGI2 analogs, including cicaprost, have been shown to inhibit the pro-inflammatory actions of certain leukocytes, suppress cardiac fibrosis, and block mitogenesis of certain cell types.[4][5][6] Importantly, cicaprost has been shown to strongly reduce lung and lymph node metastasis in rats, suggesting that it might be useful in cancer therapy.[7]
Reference:
[1]. Moncada, S. Biology and therapeutic potential of prostacyclin. Stroke 14(2), 157-168 (1983).
[2]. Kiriyama, M., Ushikubi, F., Kobayashi, T., et al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 122(2), 217-224 (1997).
[3]. Hildebrand, M., Staks, T., and Nieuweboer, B. Pharmacokinetics and pharmacodynamics of cicaprost in healthy volunteers after oral administration of 5 to 20 micrograms. European Journal of Clinical Pharmacology 39(2), 149-153 (1990).
[4]. Zhou, W., Hashimoto, K., Goleniewska, K., et al. Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. Journal of Immunology 178, 702-710 (2007).
[5]. Chan, E.C., Dusting, G.J., Guo, N., et al. Prostacyclin receptor suppresses cardiac fibrosis: Role of CREB phosphorylation. Journal of Molecular and Cellular Cardiology 49, 176-185 (2010).
[6]. Castagnino, P., Kothapalli, D., Hawthorne, E.A., et al. Cell-type- and cell-cycle-specific anti-mitogenesis by cicaprost. Prostaglandins & Other Lipid Mediators 93, 20-24 (2010).
[7]. Schirner, M., Kraus, C., Lichtner, R.B., et al. Tumor metastasis inhibition with the prostacyclin analogue cicaprost depends on discontinuous plasma peak levels. Prostaglandins, Leukotrienes and Essential Fatty Acids 58(40, 311-317 (1998).
| Cas No. | 94079-80-8 | SDF | |
| Synonyms | ZK 96480 | ||
| Chemical Name | 2-[2-[(2E,3aS,4S,5R,6aS)-hexahydro-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methyl-1,6-nonadiyn-1-yl]-2(1H)-pentalenylidene]ethoxy]-acetic acid | ||
| Canonical SMILES | O[C@@H]1C[C@H](C/2)[C@H](CC2=C\COCC(O)=O)[C@H]1C#C[C@@H](O)[C@@H](C)CC#CCC | ||
| Formula | C22H30O5 | M.Wt | 374.5 |
| Solubility | 25mg/mL in DMSO, 30mg/mL in ethanol or DMF | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6702 mL | 13.3511 mL | 26.7023 mL |
| 5 mM | 0.534 mL | 2.6702 mL | 5.3405 mL |
| 10 mM | 0.267 mL | 1.3351 mL | 2.6702 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *